Abstract
A novel androgen receptor (AR) degradation enhancer ASC-J9® has displayed beneficial effects during the in vitro and in vivo studies for treatment of prostate cancer, liver cancer, bladder cancer and spinal and bulbar muscular atrophy (SBMA). It works mainly via the degradation of AR with minimal side effects on the tested mice. Here we developed a fast, robust and more sensitive method for the quantification of ASC-J9® in 100μL of mouse serum by using liquid chromatography tandem mass spectrometry (LC–MS/MS). The limit of quantification (LOQ) was found to be 5nM for ASCJ9®. This method was successfully applied to investigate the pharmacokinetics of ASC-J9® in mice serum samples and also the distribution of the drug in various mice organs after single dose injection with results showing that ASC-J9® could be quickly absorbed in vivo and had a relatively slow elimination half-life of 5.45h. The ASC-J9® also exhibited a higher tendency to accumulate in organs such as liver, testes and prostate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
